{"title":"Gain","authors":"D. deSá","doi":"10.5040/9781474284776.386","DOIUrl":null,"url":null,"abstract":"Clinical Science, ABSTRACT: Background: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dys-regulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist samidorphan (OLZ/SAM) vs olanzapine for","PeriodicalId":390519,"journal":{"name":"Instrumentation Fundamentals for Process Control","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Instrumentation Fundamentals for Process Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5040/9781474284776.386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Clinical Science, ABSTRACT: Background: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dys-regulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist samidorphan (OLZ/SAM) vs olanzapine for
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
